Swedish medical technology company Mölnlycke Health Care has started construction on the expansion of its $135m wound care manufacturing facility in Brunswick, Maine, US.

The facility expansion aims to enhance the company’s production capacity in the US.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will incorporate renewable energy solutions, such as wind and solar power, to meet Mölnlycke’s sustainability targets.

Additionally, the plant will feature advanced machinery from suppliers in the US.

Over the coming five years, the expansion is expected to boost employment in Maine by approximately 10% and involve local contractors and suppliers.

Mölnlycke said the move aligns with its strategy to localise manufacturing and address the increasing demand from US healthcare providers.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Mölnlycke CEO Zlatko Rihter said: “This expansion is a bold step forward for Mölnlycke in the US.

“It reinforces our mission to free patients and caregivers from the burden of wounds, strengthens supply resilience, and helps us to deliver high-quality wound care solutions faster, smarter, and more sustainably.”

The project was kicked off with a groundbreaking ceremony attended by key political figures, including US Senator Angus King and Maine governor Janet Mills.

Mölnlycke aims to improve the accessibility of its advanced wound care products for US patients through this development.

“Today isn’t just about breaking ground. It’s about being bold, embracing partnerships and leading with passion,” said Chris Biddle, general manager for Mölnlycke’s US wound care production.

“Thank you to everyone who helped bring this vision to reality. The expansion is a win for Mölnlycke, for the local community and, ultimately, for the patients we serve.”

Earlier this year, the company signed a $400m financing agreement with the Swedish Export Credit Corporation (SEK) to support its growth and development. 

The ten-year arrangement aims to underpin the company’s global growth and strategic initiatives.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact